Cover Image
市場調查報告書

VistaGen Therapeutics , Inc. AS的產品平台分析

VistaGen Therapeutics , Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 259344
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
VistaGen Therapeutics , Inc. AS的產品平台分析 VistaGen Therapeutics , Inc. - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 24 Pages
簡介

VistaGen TherapeuticsInc.是總公司設置於美國的生物製藥企業,利用人體多功能幹細胞(hPSC)技術平台來製造心細胞及肝細胞,產品用於再生醫療。

本報告提供VistaGen Therapeutics , Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

VistaGen Therapeutics , Inc. 的基本資料

  • VistaGen Therapeutics , Inc. 概要
  • 主要資訊
  • 企業資料

VistaGen Therapeutics , Inc. :R&D概要

  • 主要的治療範圍

VistaGen Therapeutics , Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

VistaGen Therapeutics , Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 藥物研發階段的產品/聯合治療模式

VistaGen Therapeutics , Inc. :藥物簡介

  • AV-101
  • Stem Cell Therapy for Cartilage Repair
  • Stem Cell Therapy for Heart Repair
  • Stem Cell Therapy for Hematological Disorders
  • Stem Cell Therapy for Liver Repair

VistaGen Therapeutics , Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

VistaGen Therapeutics , Inc. :最新的開發平台資訊

VistaGen Therapeutics , Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06926CDB

Summary

Global Markets Direct's, 'VistaGen Therapeutics , Inc. - Product Pipeline Review - 2015', provides an overview of the VistaGen Therapeutics , Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of VistaGen Therapeutics , Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of VistaGen Therapeutics , Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of VistaGen Therapeutics , Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the VistaGen Therapeutics , Inc.'s pipeline products

Reasons to buy

  • Evaluate VistaGen Therapeutics , Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of VistaGen Therapeutics , Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the VistaGen Therapeutics , Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of VistaGen Therapeutics , Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of VistaGen Therapeutics , Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of VistaGen Therapeutics , Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • VistaGen Therapeutics , Inc. Snapshot
    • VistaGen Therapeutics , Inc. Overview
    • Key Information
    • Key Facts
  • VistaGen Therapeutics , Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • VistaGen Therapeutics , Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • VistaGen Therapeutics, Inc. - Pipeline Products Glance
    • VistaGen Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • VistaGen Therapeutics , Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • VistaGen Therapeutics , Inc. - Drug Profiles
    • AV-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Cartilage Repair
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Heart Repair
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Hematological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Liver Repair
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • VistaGen Therapeutics, Inc. - Pipeline Analysis
    • VistaGen Therapeutics, Inc. - Pipeline Products by Target
    • VistaGen Therapeutics, Inc. - Pipeline Products by Route of Administration
    • VistaGen Therapeutics, Inc. - Pipeline Products by Molecule Type
    • VistaGen Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • VistaGen Therapeutics , Inc. - Recent Pipeline Updates
  • VistaGen Therapeutics , Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • VistaGen Therapeutics , Inc., Key Information
  • VistaGen Therapeutics , Inc., Key Facts
  • VistaGen Therapeutics , Inc. - Pipeline by Indication, 2015
  • VistaGen Therapeutics , Inc. - Pipeline by Stage of Development, 2015
  • VistaGen Therapeutics , Inc. - Monotherapy Products in Pipeline, 2015
  • VistaGen Therapeutics , Inc. - Phase I, 2015
  • VistaGen Therapeutics , Inc. - Discovery, 2015
  • VistaGen Therapeutics , Inc. - Pipeline by Target, 2015
  • VistaGen Therapeutics , Inc. - Pipeline by Route of Administration, 2015
  • VistaGen Therapeutics , Inc. - Pipeline by Molecule Type, 2015
  • VistaGen Therapeutics , Inc. - Pipeline Products by Mechanism of Action, 2015
  • VistaGen Therapeutics , Inc. - Recent Pipeline Updates, 2015

List of Figures

  • VistaGen Therapeutics , Inc. - Pipeline by Top 10 Indication, 2015
  • VistaGen Therapeutics , Inc. - Pipeline by Stage of Development, 2015
  • VistaGen Therapeutics , Inc. - Monotherapy Products in Pipeline, 2015
  • VistaGen Therapeutics , Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top